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Abstract
International commitments to reduce the prevalence of non-communicable disease have led the Government of Saudi
Arabia to invest more in research related to cardiovascular disease. However, the strength of evidence derived from these
research activities remains unclear. The aim of our study was to examine the level of evidence within clinical Cardio-
vascular Medicine research in Saudi Arabia. We conducted a systematic review of published articles that included a
population from Saudi Arabia. Electronic databases EMBASE and MEDLINE (Ovid) were searched up to 25th of April
2021, supplemented by a second search in CENTRAL (Cochrane Central Register of Controlled Trials) and www.
clinicaltrials.gov. In addition, the Snowball- and Pearl-growing methods of search were conducted for finding addi-
tional eligible articles. Finally, a search was conducted in PubMed database for all eligible articles published by Journal
of the Saudi Heart Association from the first indexed issue up to April 2021. Level of evidence of reviewed articles was
determined using the Oxford Level of Evidence 2 scale. We calculated the mean level of evidence over 5-year periods,
and explored evidence for a time trend for number of published articles and LOE using linear regression. Of the 1113
records identified, 418 met the inclusion criteria for analysis. The articles were published between September 1986 and
March 2021. More than half of the included articles were level IV studies (n ¼ 242, 57.8%). Furthermore, we observed no
trend over the years for increased mean of level of evidence (b ¼ ¡0.07, 95% CI [-0.20, ¡0.06], p ¼ 0.236). Overall, the
level of evidence produced by the articles in clinical Cardiovascular Medicine in Saudi Arabia is very low. Prioritizing
higher-quality research is critical to produce the clinical practices and policies necessary to reduce the burden of car-
diovascular diseases in Saudi Arabia.
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1. Introduction
C ardiovascular diseases (CVDs) are a growingpublic health concern, especially in Saudi
Arabia. CVDs remain the leading cause of morbidity
and mortality in the country, with their prevalence
only projected to increase in the coming decades
[1e4]. By 2035, the economic burden of CVDs in
Saudi Arabia, including both direct and indirect
costs, is projected to increase threefold to US$ 9.8
billion [3].
International commitments to reduce the preva-
lence of non-communicable disease have led the
Government of Saudi Arabia to invest more in
CVDs-related research; however, the quality of this
research remains unclear [5e7]. In 2015, the Gov-
ernment of Saudi Arabia signed Agenda 2030 for
Sustainable Development. This agenda includes
Target 3.4, which aims to reduce by one-third pre-
mature mortality from non-communicable diseases,
including CVDs, by 2030. High-quality research and
evidence are needed to guide clinical practice and
health policy to achieve this target [5,7].
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The rise of CVDs within Saudi Arabia has led the
government to invest significantly in CVDs-related
research; however, the quality of this research re-
mains unclear [6,7]. The “Levels of Evidence (LOE)”
ranking system by the Oxford Centre for Evidence
Based Medicine is one of the standard models used
to determine the quality of evidence-based research
[8e10]. The model grades studies as level I, II, III, IV,
or V based on quantity of data, study question
(diagnosis, prognosis, treatment, screening), as well
as study benefits and harms [8]. To date, the litera-
ture has examined the LOE within Saudi publica-
tions across various clinical disciplines, including
gastroenterology and oncology. To the best of our
knowledge, no studies have examined the LOE
within Cardiovascular Medicine [11e15]. Thus, our
aim is to examine the LOE within clinical Cardio-
vascular Medical research in Saudi Arabia.
2. Materials and methods
We conducted a systematic review according to
the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) statement [16].
This study protocol was submitted to the interna-
tional prospective register of systematic reviews
(PROSPERO). Risk of bias within and across studies
was not assessed. Ethical approval was not required
as primary data have not been collected.
2.1. Electronic searches
Electronic databases EMBASE and MEDLINE
were searched on the 25th of April 2021, with re-
striction to human studies in the English language.
There were no restrictions to publication year. We
used the platform Ovid SP, and identified keywords
and index terms from key to conduct a second
search in CENTRAL (Cochrane Central Register of
Controlled Trials) and in www.clinicaltrials.gov. The
Snowball- and Pearl-growing methods of search
were conducted for finding additional eligible arti-
cles. Finally, a search was conducted in PubMed
database for all eligible articles published by Journal
of the Saudi Heart Association from the first
indexed issue up to April 2021. Search engines as
Google Scholar and the library of London School of
Economics and Political Science were used to find
the full text of chosen articles for review.
Search strategies were revised by a team of li-
brarians. The detailed search strategy and key-
words/MeSH-terms are shown in Supplementary
Material, Table S1.
2.2. Study selection and collection process
2.2.1. Eligibility criteria
The inclusion criteria of articles for review
included: full, peer-reviewed clinical Cardiovascular
Medicine articles; articles that had at least one
author affiliated with a Saudi institution; and articles
that included a population from Saudi Arabia. We
excluded basic science or cadaver studies, non-
human related studies, non-English articles,
instructional course lectures, non-systematic re-
views, editorial correspondences, Cochrane Re-
views, clinical guidelines, and letters to the editor.
Quality studies and economics evaluation studies
were also excluded.
2.2.2. Selection of studies
Two review authors (S.A., A.S.) independently
scanned the abstracts, titles, or both, of every article
retrieved to determine which studies should be
assessed further. They examined full texts of all
potentially relevant articles. Discrepancies were
resolved through consensus or assessed by a third
review author (B.P). The final selection of studies for
this systematic review used Rayyan QCRI in the
process of blinding results for both review authors
(S.A., A.S) [17].
2.3. Data extraction and management
Two review authors (S.A, A.S) extracted data
independently. When necessary, a third review
author (B.P.) resolved any disparities between the
two initial data extraction. Input data were saved in
a pre-specified spreadsheet of a Microsoft® 365
Excel document. The extracted data elements con-
sisted of: Publication details: last name of first
author, publication year, journal's name; study
design of the analysis (not of the data collection) for
each publication regardless of that stated by the
authors. LOE was allocated to each study according
to the Oxford Level of Evidence 2 scale (level I as
the highest-level score, level V as the lowest) [8].
Abbreviations
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We summarized data using descriptive statistics
(number of included articles, proportion each study
design type, proportion of each LOE). Stratified by 5-
year time periods, we calculated the mean LOE, and
explored, using linear regression, evidence for a time
trend for number of published articles and LOE. The
Stata 16.1 SE (StataCorp., College Station, TX, USA)
statistical package was used for statistical analysis.
3. Results
The selection process of the records is shown in
Fig. 1. We retrieved a total of 1113 records. Six
hundred and eighty-nine records were identified
from the data base search. Additionally, 632 records
were identified through other sources, of which 582
were from the Journal of Saudi Heart Association.
Four hundred and eighteen articles met the inclu-
sion criteria and were included in our review
(Found in Supplementary Material, Table S2). The
articles were published between September 1986
and March 2021. The most common type of study
design was cross-sectional studies (29.1%), followed
by case reports (27%), and retrospective studies
(21%) (Table 1). We identified four systematic re-
views, but none were restricted to randomized
controlled trials or included a meta-analysis. Of the
eight identified randomized clinical trials, two
adopted an open label design.
As for LOE, more than half of the included articles
were level IV studies (n ¼ 242, 57.8%). Level I
studies made up only 1.9% of the included articles
(n ¼ 8). As shown in Fig. 2, the trend over the years
for number of published articles increased from
only 8 articles in 1986e1990 to 163 articles in
2016e2021 (b ¼ 26.46, 95% CI [14.23, 38.69], p ¼
0.003). However, we observed no trend over the
years for increased mean of LOE (b ¼ 0.07, 95% CI
[-0.20, 0.06], p ¼ 0.236) (Table 2).
4. Discussion
The aim of our study was to examine the LOE
within clinical Cardiovascular Medicine research in
Saudi Arabia. Our systematic review examined 418
articles in clinical Cardiovascular Medicine.
Reviewed articles had at least one author affiliated
with a Saudi institution and included a population
from Saudi Arabia. All articles were published be-
tween September 1986 and March 2021, the number
of articles has increased throughout the years.
Our results indicate that there is a lack of high-
level evidence within clinical Cardiovascular
Medicine in Saudi Arabia. The majority of articles
were graded as level IV studies. Notably, the pro-
portion of articles classified as level I, II, III, or IV
remained constant across the three decades. We did
note a significant increase in the number of publi-
cations after 2011, marking the year the Journal of
the Saudi Heart Association re-emerged as an on-
line journal. Examining how and why the switch of
Saudi journals to online platforms impacts reader-
ship and research may be crucial to understanding
this trend.
The results of our study reflect those found by
others on research from Saudi Arabia, both within
and outside Cardiovascular Medicine. Saquib et al.
conducted a bibliometric analysis examining the
types of CVDs research performed in Saudi Arabia
from 1987 to 2017. They found that experimental
design constituted only 3% of all research studies,
and less than 9% of all studies included a hypoth-
esis-testing design [7]. These results are in agree-
ment with our findings, as only 18.8% of studies
reviewed had a LOE of I or II. The results of our
study also reflect those found in LOE analyses of
other medical disciplines within Saudi Arabia.
Studies on the LOE of Saudi Arabian publications in
the fields of gastroenterology, plastic surgery, or-
thopaedic surgery, oncology, and neurosurgery
found between 80 and 91% of the articles they
reviewed had a LOE grade of IV [11e15].
The LOE found in Saudi Arabia is low compared
to those produced in North America and Europe. A
study found most published orthopaedic studies in
Saudi Arabia had a LOE of IV in contrast to North
American studies, which contained a higher pro-
portion of high-level studies (p < 0.05) [14]. The
consistent presentation of low-grade evidence in
research across medical disciplines in Saudi Ara-
biadespecially when contrasted with the high-level
evidence present in European and North American
publicationsd brings to question whether there are
national barriers impeding the production of high-
quality evidence. The literature indicates that
despite the increase in funding towards biomedical
research in Saudi Arabia, local health practitioners
still face many challenges that impede their ability
to conduct high-level clinical research [7,18,19]. A
cross sectional survey, conducted in 2019, suggested
that the primary challenge was the inability to find
the necessary human resources to conduct high-
quality research [18]. Higher level studies often
employ study coordinators to absorb the heavy task
of enrolling, assessing, and following patients.
Further challenges include the availability of data
extraction technologies and support for statistical
designs and interpretation. The lack of human












resources available in academic and clinical settings
within Saudi Arabia may be why researchers are
more prone to utilise simpler and less rigorous
methodologies, graded as low LOE. Interestingly,
Alzahrani also noted that academic staff were not
encouraged to publish and conduct research as
much as those from European or North American
institutions [19]. These challenges may impede the
production of high-quality evidence-based research
in Saudi Arabia.
Saudi Arabia faces many challenges that impede
the ability of clinicians and academics to produce
high-level publications; however, it should be noted
that low LOE is not an issue exclusive to Saudi
Arabia. There is a lack of high-level evidence-based
Fig. 1. Study selection process.
Table 1. Classification of included articles according to study design.
Type of study design Frequency (%)
Systematic reviews 4 (0.96)
Randomized clinical trials 8 (1.91)
Prospective studies 71 (16.99)
Retrospective studies 88 (21.05)
Cross-sectional studies 12 (29.43)
Case series 11 (2.63)
Case reports 113 (27.03)
Total 418 (100)












research within clinical Cardiovascular Medicine
worldwide. Researchers examined the proportion
and LOE of research that supported American
College of Cardiology/American Heart Association
(ACC/AHA) and European Society of Cardiology
(ESC) recommendations between 2008 and 2018.
They found the proportion of those supported by
level I & II evidence categories remains small [20].
Furthermore, they found the proportions of level I &
II evidence did not increase between 2008 and 2018.
Van Dijk et al. found comparable results when
examining evidence levels supporting European
Society of Cardiology guideline recommendations
[21].
CVDs remain an urgent public health concern
throughout Saudi Arabia. The production of high-
level, evidence-based research on the Saudi Arabian
population is key to crafting national guidelines that
can promote efficient and locally targeted recom-
mendations. Funding should be prioritised for well-
designed studies that would provide higher LOE,
address priority questions and represent adequate
sample of the population in Saudi Arabia.
This study has a few limitations. First, several
studies were in fact a cross-sectional analysis of a
given disease over the span of a selected time period
without any follow-up of the outcome and without
temporal precedence of the risk factors; although, a
retrospective cohort study or retrospective review,
was specified as the design by the authors. We
recategorized these studies based on sometimes
limited methodological descriptions to the best of
our understanding. This might have led to errors
and influenced the LOE classification of each study.
Second, we did not examine the quality of each
study in-depth, which may influence the LOE clas-
sification of each article. We considered using other
validated scales that evaluate in-detail elements of
each study, but many studies did not provide
enough detail enabling such rigorous scrutiny.
5. Conclusion
The overall number of LOE I studies in clinical
Cardiovascular Medicine in Saudi Arabia is very
low. Despite increased number of published arti-
cles, we did not see a trend toward producing
higher evidence studies over the last three decades.
Future research in Saudi Arabia should focus on
producing stronger evidence that represents the
local and national priorities.
Fig. 2. Number published articles in clinical Cardiovascular Medicine in Saudi Arabia with their proportion of level of evidence over the years
(Stratified by 5-Year time periods).
Table 2. Levels of evidence of clinical Cardiovascular Medicine research
in Saudi Arabia (Stratified by 5-Year time periods).
Period Level of evidence frequency (%) Mean
Level I Level II Level III Level IV
1986e1990 0 (0.0) 0 (0.0) 0 (0.0) 8 (100.0) 4
1991e1995 0 (0.0) 2 (25.0) 2 (25.0) 4 (50.0) 3.3
1996e2000 0 (0.0) 1 (5.9) 4 (23.5) 12 (70.6) 3.6
2001e2005 1 (2.5) 11 (27.5) 8 (20.0) 20 (50.0) 3.2
2006e2010 0 (0.0) 6 (10.9) 10 (18.2) 39 (70.9) 3.6
2011e2015 3 (2.4) 20 (15.7) 24 (18.9) 80 (63.0) 3.4
2016e2021a 4 (2.5) 31 (19.0) 49 (30.1) 79 (48.5) 3.2
Total 8 (1.9) 71 (17.0) 97 (23.2) 242 (57.9)
a Until 25/04/2021.
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